Treatment options for progressive multiple sclerosis (MS) are limited and the lack of sensitive and specific MRI biomarkers is a major hurdle in therapeutic development. A number of pathophysiological processes are repeatedly found on histology but are difficult to identify accurately on MRI. Ultra-high spatial resolution MRI of intact ex vivo brain promises to help bridge the gap between MRI and pathology. We demonstrate progress towards visualizing potential biomarkers for progressive MS.
No takes yet. Share an insight, caveat, or question.
Sakaie et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: